Page contentsPage contents Key facts Decision Key facts Active substance hafnium oxide Therapeutic area Neoplasms benign, malignant and unspecified (incl cysts and polyps) Decision number EMA/PE/0000239193 PIP number EMA/PE/0000239193 Pharmaceutical form(s) Suspension for injection Condition(s) / indication(s) Treatment of head and neck epithelial malignant neoplasms Route(s) of administration Intratumoral useIntralesional use Contact for public enquiries Janssen Cilag International Email: contact@Janssen-emea.com Tel. +32 14602111 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 14/04/2025 Compliance check done No Decision EMA/PE/0000239193: EMa decision of 14 April 2025 on the granting of a product specific waiver for hafnium oxideAdopted Reference Number: EMADOC-1700519818-2035628 English (EN) (165.82 KB - PDF)First published: 01/07/2026 View Share this page